Lenalidomide‐induced tumour flare reaction in mantle cell lymphoma
Open Access
- 29 September 2010
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 151 (4), 410-412
- https://doi.org/10.1111/j.1365-2141.2010.08376.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphomaAmerican Journal of Hematology, 2009
- Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003)Journal of Clinical Oncology, 2009
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphomaBritish Journal of Haematology, 2009
- Lenalidomide-Associated Tumor Flare Reaction Is Manageable in Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2008
- Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood, 2008
- Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2008
- Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II StudyJournal of Clinical Oncology, 2006